Enrique Gomez Gomez
Overview
Explore the profile of Enrique Gomez Gomez including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
49
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Frantzi M, Morillo A, Lendinez G, Blanca A, Lopez Ruiz D, Parada J, et al.
Pathobiology
. 2024 Nov;
:1-10.
PMID: 39527943
Introduction: Prostate cancer (PCa) is the most frequently diagnosed cancer among men. A major clinical need is to accurately predict clinically significant PCa (csPCa). A proteomics-based 19-biomarker model (19-BM) was...
2.
Portugal-Gaspar F, Lopez-Beltran A, Paner G, Blanca A, Gomez Gomez E, Montironi R, et al.
Virchows Arch
. 2024 Jul;
485(3):535-546.
PMID: 39023556
We present the clinicopathological features of 23 cases of the giant cell subtype of urothelial carcinoma, a rare subtype of bladder cancer recognized in the current World Health Organization classification...
3.
Castillero A, Morales L, Gomez Gomez E, Hernandez J
Arch Esp Urol
. 2023 Aug;
76(5):363-368.
PMID: 37545156
Objective: To expose our clinical experience in the management of the penis fracture and make a literature review about this topic. Methods: We present a case of a 49 years...
4.
Gomez Gomez E, Cano Castineira R, Burgos J, Rodriguez Antolin A, Miles B, Martinez Salamanca J, et al.
Prostate
. 2023 Jul;
83(14):1323-1331.
PMID: 37409738
Background: Current pathways in early diagnosis of prostate cancer (PCa) can lead to unnecessary biopsy procedures. Here, we used telomere analysis to develop and evaluate ProsTAV®, a risk model for...
5.
Chamorro Castillo L, Morales L, Ruiz Lopez D, Salguero Segura J, Valero Rosa J, Anglada Curado F, et al.
Prostate
. 2023 Mar;
83(8):765-772.
PMID: 36895160
Introduction: Active surveillance (AS) is considered a suitable management practice for those patients with low-risk prostate cancer (PCa). At present, however, the role of multiparametric magnetic resonance imaging (mpMRI) in...
6.
Castillero A, Gomez Gomez E, Hernandez J, Prieto Castro R
Arch Esp Urol
. 2022 Sep;
75(6):580-583.
PMID: 36138510
Objective: To describe two cases of man with the diagnosis of ischemic priapism after the intake of tamsulosin and to revise the scientific literature. Methods: We present two cases of...
7.
Gomez Gomez E, Puche Sanz I, Valero Rosa J, Carrasco Valiente J, Hernandez J, Anglada Curado F
Arch Esp Urol
. 2022 Mar;
75(2):156-164.
PMID: 35332885
PSA is the most widely used diagnosticand prognostic biomarker in prostate cancer (PCa).However, its lack of specificity has generated the needto search for new complementary markers. In thisscenario, blood plasma...
8.
Shah T, Reddy D, Peters M, Ball D, Kim N, Gomez Gomez E, et al.
Prostate Cancer Prostatic Dis
. 2021 Jan;
24(2):567-574.
PMID: 33504940
Introduction: Focal therapy (FT) ablates areas of prostate cancer rather than treating the whole gland. We compared oncological outcomes of FT to radical prostatectomy (RP). Methods: Using prospective multicentre databases...
9.
Rubio Galisteo J, Fernandez L, Gomez Gomez E, de Pedro N, Cano Castineira R, Pedregosa A, et al.
Prostate Cancer Prostatic Dis
. 2020 May;
24(1):88-95.
PMID: 32367011
Background: The objective of this study was to explore telomere-associated variables (TAV) as complementary biomarkers in the early diagnosis of prostate cancer (PCa), analyzing their application in risk models for...
10.
Gomez Gomez E, Salamanca Bustos J, Carrasco Valiente J, Fernandez Rueda J, Blanca A, Valero Rosa J, et al.
BMJ Open
. 2019 Nov;
9(11):e031032.
PMID: 31722940
Introduction: Risk calculators (RCs) are easy-to-use tools considering available clinical variables that could help to select those patients with risk of prostate cancer (PCa) who should undergo a prostate biopsy....